|
Deep Breadth: GSK Doubles Down on COPD and Asthma
PharmExec.com (blog) Approved in November, GSK's fluticasone furoate/vilanterol dry powder combo inhaler for Chronic Obstructive Pulmonary Disease (COPD) and asthma* – sold as Breo Ellipta in the US, and Relvar Ellipta in Europe, Mexico and Japan – is the first of four … |
View full post on asthma – Google News